Salarius Pharmaceuticals (SLRX) Peer Comparison

$0.62

$-0.20 (-24.37%)

As on 05-Feb-2026 09:30EDT

Market cap

$5 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.1

Div. Yield

0 %

Edit

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Market cap ($ Mln)	5	39	15
Revenue ($ Mln)	--	-118	1
Net Profit ($ Mln)	-5.00	215.65	-18.14
Net Margin (%)	-113,076.32	-182.61	-1,815.62
RoE (%)	-232.24	--	--
Price to Earnings	--	--	--
Price-To-Book	1.13	53.83	7.72

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Operating Revenue	0.00	-118.09	1.00
Cost of Revenue	0.01	-20.39	17.76
Gross Profit	0.00	14.06	-48.29
Operating Expenses	5.07	26.33	81.64
Operating Profit (EBIT)	-5.07	-124.04	-98.40
Other Income	0.00	0.00	0.00
Profit before Tax	-5.00	-131.27	-18.14
Provision for Tax	0.00	-213.92	0.12
Profit after Tax (Net Income)	-5.00	215.65	-18.14
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Shareholder's Funds	4.25	-17.03	-0.56
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	0.74	83.56	2.03
Current Liabilities	1.10	35.97	32.90
Total Liabilities	3.02	214.53	86.69

Assets ($ Mln)

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Non-Current Assets	0.03	3.59	2.72
Current Assets	6.06	133.42	31.65
Total Assets	3.02	214.53	86.69
Total Debt*	0.00	19.47	2.50
Net Current Assets	4.22	97.45	-1.25

Cashflow ($ Mln)

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Cash From Operating Activities	-4.53	-138.00	-84.31
Cash Flow from Investing Activities	--	125.99	--
Cash from Financing Activities	1.06	-0.26	113.81
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
ROCE (%)	-152.54	56.26	-486.39
ROE (%)	-232.24	22.14	-529.97
ROA (%)	-78.57	68.69	-13.30
EBIT Margin (%)	-114,018.08	109.06	-10,073.57
Net Margin (%)	-113,076.32	-182.61	-1,815.62
Cash Profit Margin (%)	-25.56	0.00	0.00

Growth Ratios

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Revenue Growth (%)	-75.26	-218.29	573.46
EBIT Growth (%)	3.26	19.64	-9.05
Net Profit Growth (%)	-0.22	277.07	90.32
EPS Growth (%)	61.93	677.48	93.16
Book Value Growth (%)	-74.09	93.05	-109.44

Valuation Ratios

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Price / Earnings	-0.02	-0.04	-1.11
Price / Book Value	0.08	-0.01	2.06
Dividend Yield (%)	--	--	--
EV/EBITDA	0.37	-0.29	-0.39
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Debt to Equity	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.00	-0.83
Current Ratio	5.49	3.71	0.96
Quick Ratio	5.49	3.60	0.96
Interest Coverage	--	-14.33	--

Operating Efficiency Ratios

	Salarius Pharmaceuticals (SLRX)	FibroGen (FGEN)	Applied Therapeutics (APLT)
Debtors to sales (%)	0.00	-0.10	1,666.97
Asset Turnover	0.00	-0.38	0.01
Receivable days	--	256.07	228.78
Inventory Days	--	524.84	24.60
Payable days	63,565.68	270.21	23.14
Cash Conversion Cycle	--	510.70	230.25

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly